uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Tsolakis, Apostolos V.
Alternative names
Publications (10 of 26) Show all publications
Kanakis, G., Grimelius, L., Spathis, A., Tringidou, R., Rassidakis, G. Z., Öberg, K., . . . Tsolakis, A. V. (2015). Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role. Neuroendocrinology, 101(3), 211-222
Open this publication in new window or tab >>Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role
Show others...
2015 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 101, no 3, p. 211-222Article in journal (Refereed) Published
Abstract [en]

Objective: The expression of somatostatin receptors (SSTRs) and dopamine receptor 2 (DR2) in neuroendocrine tumors is of clinical importance as somatostatin analogues and dopamine agonists can be used for their localization and/or treatment. The objective of this study is to examine the expression of the five SSTR subtypes and DR2 in lung carcinoids (LCs). Methods: We conducted a retrospective study of 119 LCs from 106 patients [typical carcinoids (TCs): n = 100, and atypical carcinoids (ACs): n = 19]. The expression of all five SSTR subtypes and DR2 was evaluated immunohistochemically and correlated to clinicopathological data. In a subgroup of cases, receptor expression was further analyzed using semiquantitative RT-PCR. Results: SSTR2A was the SSTR subtype most frequently expressed immunohistochemically (72%), followed by SSTR1 (63%), SSTR5 (40%), and SSTR3 (20%), whereas SSTR4 was negative. DR2 was expressed in 74% and co-expressed with SSTR1 in 56%, with SSTR2A in 59%, with SSTR3 in 19%, and with SSTR5 in 37% of the tumors. Receptor expression was not related to the histological subtype, tumor aggressiveness (disease extent/grading) or functionality; however, DR2 was expressed more frequently in ACs than TCs (95 vs. 70%, p = 0.017). In a subset of patients, RT-PCR findings highly suggested that the expression of SSTR2A, SSTR3, DR2, and to a lesser extent that of SSTR1 and SSTR5 is the outcome of increased gene transcription. Conclusions: The high and variable immunohistochemical expression of the majority of SSTRs along with their co-expression with DR2 in LCs provides a rationale for their possible treatment with agents that target these receptors.

Keywords
Somatostatin receptor subtypes, Dopamine receptor 2, Immunohistochemistry, Lung carcinoids
National Category
Endocrinology and Diabetes Neurosciences
Identifiers
urn:nbn:se:uu:diva-258556 (URN)10.1159/000381061 (DOI)000356490100003 ()25765100 (PubMedID)
Available from: 2015-07-15 Created: 2015-07-15 Last updated: 2018-01-11Bibliographically approved
Tsolakis, A. V., Grimelius, L., Granerus, G., Stridsberg, M., Falkmer, S. E. & Janson, E. T. (2015). Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours. World Journal of Gastroenterology, 21(47), 13240-13249
Open this publication in new window or tab >>Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours
Show others...
2015 (English)In: World Journal of Gastroenterology, ISSN 1007-9327, E-ISSN 2219-2840, Vol. 21, no 47, p. 13240-13249Article in journal (Refereed) Published
Abstract [en]

AIM:

To study histidine decarboxylase (HDC) expression in normal and neoplastic gastric neuroendocrine cells in relationship to the main histamine metabolite.

METHODS:

Control tissues from fundus (n = 3) and corpus (n = 3) mucosa of six patients undergoing operations for gastric adenocarcinoma, biopsy and/or gastric surgical specimens from 64 patients with primary gastric neuroendocrine tumours (GNETs), as well as metastases from 22 of these patients, were investigated using conventional immunohistochemistry and double immunofluorescence with commercial antibodies vs vesicular monoamine transporter 2 (VMAT-2), HDC and ghrelin. The urinary excretion of the main histamine metabolite methylimidazoleacetic acid (U-MeImAA) was determined using high-performance liquid chromatography in 27 of the 64 patients.

RESULTS:

In the gastric mucosa of the control tissues, co-localization studies identified neuroendocrine cells that showed immunoreactivity only to VMAT-2 and others with reactivity only to HDC. A third cell population co-expressed both antigens. There was no co-expression of HDC and ghrelin. Similar results were obtained in the foci of neuroendocrine cell hyperplasia associated with chronic atrophic gastritis type A and also in the tumours. The relative incidence of the three aforementioned markers varied in the tumours that were examined using conventional immunohistochemistry. All of these GNETs revealed both VMAT-2 and HDC immunoreactivity, and their metastases showed an immunohistochemical pattern and frequency similar to that of their primary tumours. In four patients, increased U-MeImAA excretion was detected, but only two of the patients exhibited related endocrine symptoms.

CONCLUSION:

Human enterochromaffin-like cells appear to partially co-express VMAT-2 and HDC. Co-expression of VMAT-2 and HDC might be required for increased histamine production in patients with GNETs.

Keywords
Enterochromaffin-like cells, High performance liquid chromatography, Gastric neuroendocrine tumours, Histidine decarboxylase, Immunohistochemistry, Urinary excretion of the main histamine metabolite methylimidazoleacetic acid, Vesicular monoamine transporter 2
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-274442 (URN)10.3748/wjg.v21.i47.13240 (DOI)000366889600004 ()26715806 (PubMedID)
Available from: 2016-01-21 Created: 2016-01-21 Last updated: 2017-11-30Bibliographically approved
Tsolakis, A., James, P., Zhang, M., Belletrutti, P., Mohamed, R., Roberts, D. & Heitman, S. (2015). Incremental Benefit of Preoperative Endoscopic Ultrasound for the Detection of Pancreatic Neuroendocrine Tumors: A Meta-Analysis. Paper presented at 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 11-13, 2015, Barcelona, SPAIN. Neuroendocrinology, 102(1-2), 116-116
Open this publication in new window or tab >>Incremental Benefit of Preoperative Endoscopic Ultrasound for the Detection of Pancreatic Neuroendocrine Tumors: A Meta-Analysis
Show others...
2015 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 102, no 1-2, p. 116-116Article in journal, Meeting abstract (Other academic) Published
Keywords
pancreatic neuroendocrine tumor, radiological investigation, incremental benefit, endoscopic ultrasound
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-266079 (URN)10.1159/000431385 (DOI)000361683500108 ()
Conference
12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 11-13, 2015, Barcelona, SPAIN
Available from: 2015-11-05 Created: 2015-11-05 Last updated: 2017-12-01Bibliographically approved
James, P. D., Tsolakis, A. V., Zhang, M., Belletrutti, P. J., Mohamed, R., Roberts, D. J. & Heitman, S. J. (2015). Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointestinal Endoscopy, 81(4), 848-+
Open this publication in new window or tab >>Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis
Show others...
2015 (English)In: Gastrointestinal Endoscopy, ISSN 0016-5107, E-ISSN 1097-6779, Vol. 81, no 4, p. 848-+Article, review/survey (Refereed) Published
Abstract [en]

Background: Current guidelines recommend CT scan or magnetic resonance imaging as the initial imaging modalities for the work-up of suspected pancreatic neuroendocrine tumors (PNETs). Objective: To determine the incremental benefit of preoperative EUS (IBEUS) for the detection of suspected PNETs after other investigative modalities have been attempted. Design: This systematic review searched MEDLINE, EMBASE, bibliographies of included articles, and conference proceedings for studies reporting original data regarding the preoperative detection of PNETs. Pooled IBEUS was calculated by using random effects models. Heterogeneity was explored by using stratified meta-analysis and meta-regression. Evidence of small-study effects was assessed by using funnel plots and the Begg test. Patients: Patients with suspected PNETs. Interventions: EUS evaluation. Main Outcome Measurements: The pooled IBEUS for the detection of PNETs after CT scan, with or without additional investigative modalities. Results: Among 4505 citations identified, we included 17 cohort studies (612 patients). EUS identified PNETs in 97% of cases. Improved PNET identification with EUS was observed in all of the studies. After adjusting for small-study effects, meta-analysis showed that EUS alone could identify PNETs in approximately 1 in 4 patients (adjusted IBEUS 26%; 95% confidence interval, 17%-37%). The pooled IBEUS varied based on the study design, study size, type of CT scan used, and the number of modalities used prior to EUS. Limitations: The majority of included studies were retrospective. Small-study effects were observed. Conclusion: Preoperative EUS is associated with an increase in PNET detection after other modalities are attempted.

National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-252458 (URN)10.1016/j.gie.2014.12.031 (DOI)000351668700006 ()25805462 (PubMedID)
Available from: 2015-05-07 Created: 2015-05-07 Last updated: 2017-12-04Bibliographically approved
Diakatou, E., Alexandraki, K. I., Tsolakis, A. V., Kontogeorgos, G., Chatzellis, E., Leonti, A. & Kaltsas, G. A. (2015). Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. Clinical Endocrinology, 83(3), 420-428
Open this publication in new window or tab >>Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores
Show others...
2015 (English)In: Clinical Endocrinology, ISSN 0300-0664, E-ISSN 1365-2265, Vol. 83, no 3, p. 420-428Article in journal (Refereed) Published
Abstract [en]

ContextThe expression of somatostatin (sstr1-5) and dopamine (DR) receptors in neuroendocrine neoplasms (NENs) facilitates diagnosis by tumour visualization with somatostatin receptor scintigraphy (SRS) and directs towards specific treatment with peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues. ObjectiveTo investigate the co-expression of sstrs, D2R in relation to pre-operative SRSs in NENs. DesignProspective two-centre study. Patients and measurementsWe analysed pre-operative SRS of 60 patients [44 with gastrointestinal (GI) NENs and 16 with lung NENs] and compared SRS results with immunohistochemical (IHC) reactivity for sstr2, sstr3, sstr5 in sample tissues from primary (n=54) and metastatic (n=27) lesions and IHC reactivity for D2R in 23 samples from primary GI-NENs lesions. ResultsSstr2 was the commonest sstr expressed (654%) and was co-expressed with sstr3 and sstr5 in 321% and 247% of the specimens, respectively. In 67 of 81 specimens (827%), there was concordance of sstr2 immunohistochemistry with SRS findings (P<0001). D2R was expressed in only 8 of 23 (348%) GI-NENs while was co-expressed with sstr2 in all cases. SRS grade, as per Krenning scale, was higher in metastatic foci, large-size (>2cm) tumours and GI-NENs, whereas sstr2 intensity was greater in GI compared to lung NENs. SRS grade showed higher correlation with sstr2 (r=06, P<0001) and D2R (r=05, P<0001) IHC intensity scores than tumour size (r=04, P<0001) and sstr3 (r=04, P<0001) intensity score. ConclusionsSstr2 IHC expression and SRS are useful tools for the diagnosis and management of NENs because they display a high concordance. IHC expression of DR2 seems to be of potential clinical significance in GI-NENs tumours.

National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-262956 (URN)10.1111/cen.12775 (DOI)000360459600022 ()25808161 (PubMedID)
Available from: 2015-09-29 Created: 2015-09-23 Last updated: 2017-12-01Bibliographically approved
Spargias, K., Bouboulis, N., Halapas, A., Chrissoheris, M., Skardoutsos, S., Nikolaou, J., . . . Pattakos, S. (2015). Transaortic aortic valve replacement using the Edwards Sapien-XT Valve and the Medtronic CoreValve: initial experience. Hellenic Journal of Cardiology, 55(4), 288-293
Open this publication in new window or tab >>Transaortic aortic valve replacement using the Edwards Sapien-XT Valve and the Medtronic CoreValve: initial experience
Show others...
2015 (English)In: Hellenic Journal of Cardiology, ISSN 1109-9666, Vol. 55, no 4, p. 288-293Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION: Transcatheter aortic valve replacement (TAVR) is now an established treatment for certain patients with severe aortic valve stenosis (AS). However, as the number of patients screened for TAVR increases, many are found to have absolutely no option for peripheral artery access. Transaortic valve replacement (TAoVR) has been proposed as a new alternative route in patients deemed unsuitable for conventional approaches. We present our first series of TAoVR cases using the Edwards Sapien-XT and the Medtronic CoreValve prostheses.

METHODS: Twenty-five (25) symptomatic patients (mean age 78 ± 8 years, mean logistic EuroSCORE I 25 ± 11%) with severe AS underwent TAoVR using the Sapien-XT valve (10 patients) or the CoreValve (15 patients).

RESULTS: The mean fluoroscopy time was 15.6 ± 4.2 minutes, the mean time in the intensive care unit was 1.9 ± 1.0 days, and the mean hospital stay was 6.4 ± 1.6 days. The mean effective aortic valve area increased (from 0.68 ± 0.15 cm(2) to 1.82 ± 0.34 cm(2), p<0.001) and the mean transvalvular pressure gradient declined (from 48 ± 15 mmHg to 9 ± 5 mmHg, p<0.05) post implantation. The procedural mortality was 0% and the in-hospital mortality was 4% (one death at day 3 due to cardiogenic shock). The mean NYHA functional class improved from 3.2 ± 0.4 to 1.5 ± 0.9 at 30 days.

CONCLUSIONS: Our initial experience with the TAoVR approach using both the Edwards Sapien-XT and the Medtronic CoreValve prosthesis demonstrated that it could be performed safely, resulting in substantial acute echocardiographic and early clinical improvement.

National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-244251 (URN)000344038100004 ()25039024 (PubMedID)
Available from: 2015-02-13 Created: 2015-02-13 Last updated: 2017-12-04Bibliographically approved
Lyros, I., Fora, E., Damaskos, S., Stanko, P. & Tsolakis, A. (2014). An incidental finding on a diagnostic CBCT: a case report. Australian orthodontic journal, 30(1), 67-71
Open this publication in new window or tab >>An incidental finding on a diagnostic CBCT: a case report
Show others...
2014 (English)In: Australian orthodontic journal, ISSN 0587-3908, Vol. 30, no 1, p. 67-71Article in journal (Refereed) Published
Abstract [en]

It is known that Cone Beam Computed Tomography (CBCT) provides reliable spatial data and has many clinical applications for dental and particularly orthodontic patients. The present article provides a short review of the literature and reports an unusual CBCT finding in an orthodontic patient referred for the assessment of impacted upper canines. A unilateral lesion in the left maxillary sinus, was an incidental finding. Following a histological examination, which revealed unilateral nasal polyps, surgical removal was performed as the treatment of choice.

National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-244252 (URN)000339592800010 ()24968648 (PubMedID)
Available from: 2015-02-13 Created: 2015-02-13 Last updated: 2015-04-24Bibliographically approved
Kaltsas, G., Grozinsky-Glasberg, S., Alexandraki, K. I., Thomas, D., Tsolakis, A. V., Gross, D. & Grossman, A. B. (2014). Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms. Clinical Endocrinology, 81(2), 157-168
Open this publication in new window or tab >>Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms
Show others...
2014 (English)In: Clinical Endocrinology, ISSN 0300-0664, E-ISSN 1365-2265, Vol. 81, no 2, p. 157-168Article, review/survey (Refereed) Published
Abstract [en]

The vast majority of gastrin-related gastrointestinal neuroendocrine neoplasms (GI-NENs) develop in the context of chronic atrophic gastritis (type 1), a condition closely related to autoimmune thyroid diseases. These neoplasms are defined as gastric NENs type 1 (GNEN1) and have recently been shown to constitute the commonest GI-NENs in a prospective study. GNEN1s are usually multiple and follow a relative indolent course, raising questions regarding the extent that such patients should be investigated and the appropriate therapeutic interventions needed. Recently, a number of consensus statements and guidelines have been published from various societies dealing with the diagnosis and management of GI-NENs. Endocrinologists are among the many different medical specialties involved in GNEN1s diagnosis and management. However, despite recent advances, few randomized trials are available, and thus existing evidence remains relatively weak compared to other malignancies. The purpose of this review is to provide recent evidence along with currently employed modalities addressing the diagnosis, management, long-term follow-up and potential comorbidities of GNEN1s.

National Category
Endocrinology and Diabetes Clinical Medicine
Identifiers
urn:nbn:se:uu:diva-231486 (URN)10.1111/cen.12476 (DOI)000339670500001 ()
Available from: 2014-09-09 Created: 2014-09-08 Last updated: 2017-12-05Bibliographically approved
Kanakis, G. A., Grimelius, L., Kaltsas, G. & Tsolakis, A. V. (2014). Immunohistochemical Expression of Connective Tissue Growth Factor and Insulin-like Growth Factor-1 in Lung Carcinoids. Paper presented at 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 05-07, 2014, Barcelona, SPAIN. Neuroendocrinology, 99(3-4), 289-290
Open this publication in new window or tab >>Immunohistochemical Expression of Connective Tissue Growth Factor and Insulin-like Growth Factor-1 in Lung Carcinoids
2014 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 99, no 3-4, p. 289-290Article in journal, Meeting abstract (Other academic) Published
Keywords
lung, carcinoid, ctgf, igf-1
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-237662 (URN)000343640100195 ()
Conference
11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 05-07, 2014, Barcelona, SPAIN
Available from: 2014-12-10 Created: 2014-12-03 Last updated: 2017-12-05Bibliographically approved
Glasberg, S., Thomas, D., Strosberg, J. R., Pape, U. F., Felder, S., Tsolakis, A., . . . Gross, D. J. (2014). Metastatic Type 1 Gastric Carcinoid-A Real Threat or Just a Myth?. Paper presented at 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 05-07, 2014, Barcelona, SPAIN. Neuroendocrinology, 99(3-4), 302-302
Open this publication in new window or tab >>Metastatic Type 1 Gastric Carcinoid-A Real Threat or Just a Myth?
Show others...
2014 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 99, no 3-4, p. 302-302Article in journal, Meeting abstract (Other academic) Published
Keywords
metastatic gastric carcinoids, gastrin, chromogranin a, somatostatin analogues
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-237663 (URN)000343640100230 ()
Conference
11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 05-07, 2014, Barcelona, SPAIN
Available from: 2014-12-05 Created: 2014-12-03 Last updated: 2017-12-05Bibliographically approved
Organisations

Search in DiVA

Show all publications